Comprehensive Cellular Vaccine Immune Monitoring Consortium
A collaborative program that provides standardized and research level assays for clinical and pre-clinical HIV vaccine trials.
The Comprehensive Cellular Vaccine Immune Monitoring Consortium (CCVIMC) provides centralized resources to the Collaboration for AIDS Vaccine Discovery (CAVD), for the development and licensure of a safe and broadly effective vaccine to HIV. The CCVIMC convenes leading scientists to develop, optimize and standardize cellular-immune assays for use in evaluating vaccine platforms being developed within the CAVD. Initiated in 2006, the current five-year grant focuses on expanding the consortium’s cellular immune monitoring capabilities by applying cutting-edge technologies to encompass the assessment of both T and B cell immune responses. Beyond providing exploratory, qualified and standardized cellular assays, the CCVMC also consults with vaccine-discovery laboratories to assist them in designing pre-clinical and clinical trials and provides systems biology analysis to their trial data. Scientific leadership is provided by the consortium’s Principal Investigator (PI), Richard Koup (NIAID), and administration and management of the program is directed by the FNIH.
- Duke University
- Fred Hutchinson Cancer Research Center
- National Institute of Allergy and Infectious Diseases
Results & Accomplishments
Supporting AIDS Vaccine Development
The Comprehensive Cellular Vaccine Immune Monitoring Consortium has been providing high-quality cellular immune monitoring to the Collaboration for AIDS Vaccine Development (CAVD) for more than 14 years.
For CAVD study results, click here
For more information: https://www.cavd.org/grantees/Pages/Grantee-Koup.aspx